Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Mar 17;23(3):106.
doi: 10.31083/j.rcm2303106.

Cardiorenal Impact of SGLT-2 Inhibitors: A Conceptual Revolution in The Management of Type 2 Diabetes, Heart Failure and Chronic Kidney Disease

Riccardo Nevola  1   2 , Maria Alfano  1 , Pia Clara Pafundi  3 , Chiara Brin  1 , Felice Gragnano  4   5 , Paolo Calabrò  4   5 , Luigi Elio Adinolfi  1 , Luca Rinaldi  1 , Ferdinando Carlo Sasso  1 , Alfredo Caturano  1
Affiliations
Free article
Review

Cardiorenal Impact of SGLT-2 Inhibitors: A Conceptual Revolution in The Management of Type 2 Diabetes, Heart Failure and Chronic Kidney Disease

Riccardo Nevola et al. Rev Cardiovasc Med. .
Free article

Abstract

Type 2 Diabetes Mellitus (T2DM) is associated with an elevated incidence of cardiovascular and renal diseases, responsible for mortality rates significantly higher than in the general population. The management of both cardiovascular risk and progression of kidney disease thus seem crucial in the treatment of the diabetic patient. The availability of new classes of drugs which positively affect both cardiovascular and renal risk, regardless of the glycemic control, represents a revolution in the treatment of T2DM and shifts the attention from the intensive glycemic control to a holistic management of the diabetic patient. Among these, sodium-glucose cotransporter-2 inhibitors (SGLT2i) have been associated with a remarkable reduction of cardiovascular and renal mortality, lower hospitalization rates for heart failure and lower progression of renal damage and albuminuria. Thus, their use in selected subpopulations seems mandatory. Aim of this review was the assessment of the current evidence on SGLT2i and their related impact on the cardiovascular and renal profiles.

Keywords: SGLT2i; chronic kidney disease; diabetes; gliflozin; heart failure.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest. Ferdinando Carlo Sasso is serving as one of the Editorial Board members of this journal. We declare that Ferdinando Carlo Sasso had no involvement in the peer review of this article and has no access to information regarding its peer review. Full responsibility for the editorial process for this article was delegated to Massimo Volpe, Filippos Triposkiadis, Grigorios Korosoglou and Matteo Cameli.

MeSH terms

Substances

LinkOut - more resources